Posts

Groundbreaking ceremony with Ensemble/Mosaic, Oxford, PIDC, and Councilmember Kenyatta Johnson

Ensemble/Mosaic and Oxford Properties Group Break Ground on Speculative R & D Lab Building

Ensemble/Mosaic, a joint venture between Ensemble Real Estate Investments and Mosaic Development Partners, and Oxford Properties Group (“Oxford”), a leading global real estate investor, asset manager and business builder, have broken ground on 1201 Normandy Place, a speculative 137,000 square foot R & D lab building at the Navy Yard in Philadelphia. The project represents the first new development initiated as part of Ensemble/Mosaic and Oxford’s recently executed strategic partnership.

“1201 Normandy represents a significant milestone for the Navy Yard, our new partnership with Mosaic and Oxford, and Philadelphia’s life sciences community,” said Mark Seltzer, Senior Vice President, Development-East at Ensemble. “The building will play a critical role in the life science ecosystem of the campus by creating space for smaller gene and cell therapy users and providing a place to grow as their business evolves towards commercialization and manufacturing. This is the right product, at the right time in the right location, and we are already experiencing strong interest.”

1201 Normandy Place

“The Navy Yard is a critical asset to Philadelphia’s life science community,” said Philadelphia City Councilmember Kenyatta Johnson, whose Second Council District includes the Navy Yard.  “The development of this new 137,000 square foot laboratory and office building here at 1201 Normandy Place is the first development by Ensemble Real Estate Investments and Mosaic Development Partners.  The lab building is tailored specifically to gene and cell therapy companies and will further drive economic growth at the Navy Yard, which is a major economic engine of our city.”

1201 Normandy Place is the first speculative multi-tenant R & D lab building at the Navy Yard. The building was designed in consultation with CRB, a leading lab designer, to be the most sophisticated lab building in the region optimized for cell and gene therapy R & D companies, while maintaining the flexibility to accommodate all users. The modern four-story facility will feature 137,000 square feet of highly customizable lab space and will be able to support life science customers ranging from 5,000-35,000 square feet per floor. Special user-specific considerations include 15’-16’ floor-to-floor ceiling heights, predetermined GMP space, structural integrity that minimizes vibration and two loading docks. The robust utility and safety features include a central plant HVAC system with water cooled chillers, customizable electrical output and layout as well as built-in emergency power. Occupants will also have access to collaborative workspace, an outdoor balcony on each floor and a ground level cafe. The building is projected to achieve LEED Gold Certification.  CBRE is leading the marketing  efforts for 1201 Normandy Place.

“Today’s groundbreaking builds on our partnership’s considerable momentum, as we take a major step towards delivering a world-class life science innovation hub at the heart of the Navy Yard,” said Chad Remis, Executive Vice President, North America at Oxford. “The speed at which we’ve advanced this project is testament to the relationship between Oxford and Ensemble/Mosaic—in both our vision for the project, as well as our shared conviction in Philadelphia and its continued emergence as one of the premier global biopharma markets.”

1201 Normandy will allow smaller-scale gene and cell therapy companies to take space in the Navy Yard’s thriving life science community. Currently, it is home to many world-class and well-established gene and cell therapy firms including Iovance Biotherapeutics, Adaptimmune Therapeutics PLC, WuXi Advanced Therapies Coriell Life Sciences, Vinta Bio, Inc., and is the regional headquarters of Ben Franklin Technology Partners.

“The depth of our collective development experience, this unparalleled location and our ability to move quickly are tremendous advantages for us,” said Greg Reaves, CEO and Co-Owner, Mosaic. “We designed 1201 Normandy to be at the leading edge of R & D lab space, offering customers superior utility packages and safety features. This building will truly be transformational to the life science community and the Navy Yard as a whole.”

Groundbreaking ceremony with Ensemble/Mosaic, Oxford, PIDC, and Councilmember Kenyatta Johnson

Ensemble/Mosaic and Oxford

Recently, Ensemble/Mosaic and Oxford Properties Group entered into a strategic partnership which will, over time, own and develop up to 3 million square feet of life science properties at the Navy Yard in Philadelphia. The agreement includes Oxford’s investment in five existing life science assets owned by Ensemble Real Estate Investments, and Ensemble/Mosaic’s two initial life science properties, of which 1201 Normandy is the first. In addition, Oxford will look to partner in all future life science projects on sites controlled by Ensemble/Mosaic at the Navy Yard. The deal represented Oxford’s first investment in Philadelphia and further expands the firm’s extensive life science portfolio, which includes over US$2 billion of investment activity in North America since the start of 2021.

PIDC Senior Vice President Kate McNamara considers the Ensemble/Mosaic and Oxford partnership a boon that will help continue to grow the ecosystem of the Navy Yard.

“Developing a speculative life science building that can house multiple users illustrates the strength of the market in Philadelphia and the strong interest by companies to take advantage of all the Navy Yard has to offer,” said McNamara. “This is a big milestone for the Navy Yard, Ensemble/Mosaic, Oxford, and PIDC that will create a landscape for lifesaving work and job opportunities for all Philadelphians. We’re at an important intersection of what the city needs and what will benefit the world, and it’s an exciting moment.”

Ensemble/Mosaic at the Navy Yard

In 2020, Ensemble/Mosaic announced plans for its US$2.6 billion development plan, designed to further establish the Navy Yard as a vibrant and inclusive mixed-use community. Through its agreement with PIDC—Philadelphia’s public-private economic development corporation, which oversees all management and development of the Navy Yard, the joint venture plans for approximately 3,000 residential units and more than 3 million square feet of life science manufacturing, R & D, office, hotels, makerspace and retail space when complete. In addition to 1201 Normandy and 333 Rouse, the $400+ million first phase includes the development a three-building residential complex with ground floor retail (including an AVE in partnership with Korman Communities) and a signature adaptive reuse hotel.

Sumit Verna, Iovance iCTC site head, at the ribbon cutting ceremony. He is joined by Fred Vogt, Iovance CEO, Governor Tom Wolf, and Mayor Jim Kenney.

Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC)

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), is celebrating the official opening of the Iovance Cell Therapy Center (iCTC). The iCTC, located at the Philadelphia Navy Yard, is the first centralized, scalable, state-of-the-art manufacturing facility dedicated to producing TIL cell therapies for patients with solid tumor cancers. The current capacity is expected to meet potential demand for thousands of patients per year with multiple types of cancers, including clinical trial patients and future commercial patients.

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “Since Iovance was founded, we have been dedicated to advancing novel cell therapies for patients with solid tumor cancers. As the hub of cell and gene therapy and the home of leading hospitals and academic centers, Philadelphia became the city of choice for our internal manufacturing. A little over two years after breaking ground, iCTC is now one of the largest cell therapy manufacturing facilities in the world and may ultimately house hundreds of employees. We now have the capacity to supply broad access to TIL therapies for patients. I believe that the important ecosystem within Cellicon Valley will continue to contribute to our advancements to pioneer a new class of treatment for cancer.”

A ribbon cutting event celebrates the opening with special guests including Pennsylvania Governor Tom Wolf, Philadelphia Mayor Jim Kenney, and other government officials and collaborators within Cellicon Valley. Patients, caregivers, and patient advocacy organizations, including Melanoma Research Foundation (MRF), Melanoma Research Alliance (MRA) and the Society for Gynecological Oncology’s Foundation for Women’s Cancer cut the ribbon on behalf of everyone who is currently fighting cancer, and in memory of those who lost their battles with cancer.

Sumit Verna, Iovance iCTC site head, at the ribbon cutting ceremony. He is joined by Fred Vogt, Iovance CEO, Governor Tom Wolf, and Mayor Jim Kenney.

“The iCTC is a symbol of significant innovation and opportunity for the commonwealth as hundreds of new, high-paying jobs will ultimately be created at this facility,” said Governor Tom Wolf. “Iovance has already made a positive impact on the region and worked with a great sense of urgency to complete construction and begin initial manufacturing for patients with cancer.”

“The iCTC represents a new model in cell therapy manufacturing and bolsters Philadelphia’s reputation as a leading location for technology, innovation, and life sciences,” said City of Philadelphia Mayor Jim Kenney. “Iovance is a great example of what companies from around the country and the world may accomplish in establishing Philadelphia as the place to attract talent and grow their business.”

Located at 300 Rouse Boulevard and with approximately 136,000 square feet of space, the iCTC is among the largest cell therapy manufacturing facilities today. The iCTC is currently supplying Iovance clinical studies, and commercial manufacturing is expected to begin after initial product approval. The iCTC was developed and built by Gattuso Development Partners, LLC and the design and construction management firm CRB. Financial incentives were provided by the Commonwealth of Pennsylvania, the City of Philadelphia, and PIDC, including the site’s designation as a Keystone Opportunity Improvement Zone, which allows incentives for business development.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company’s TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. For more information, please visit www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). All such written or oral statements made in this press release, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates, and our ability to successfully commercialize any product candidates for which we obtain FDA approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the new version of the protocol which further defines the patient population to include more advanced patients in our cervical cancer trial may have an adverse effect on the results reported to date; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA may differ from the interpretation of such results or communications by the FDA; the acceptance by the market of our product candidates and their potential reimbursement by payors, if approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility may adversely affect our potential commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; and other factors, including general economic conditions and regulatory developments, not within our control.

CONTACTS

Iovance Biotherapeutics, Inc:
Sara Pellegrino, IRC
Vice President, Investor Relations & Public Relations
650-260-7120 ext. 264
Sara.Pellegrino@iovance.com

Solebury Trout:
Zara Lockshin
646.378.2960
zlockshin@soleburytrout.com

Redevelopment of historic Building 624: Historic Core pedestrian plaza flanked by artisan makerspaces for authentic local retail. Credit: Groundswell

PIDC and Ensemble/Mosaic Execute Navy Yard Development Agreement, Launching $2.5 Billion Development Plan

Media Contacts: Robbie Tarpley Raffish, a.s.a.p.r. (for Ensemble/Mosaic) 410-430-9705; Jessica Calter, PIDC, 215-496-8161

PIDC, Philadelphia’s public-private economic development corporation and master developer of the Philadelphia Navy Yard, in partnership with Ensemble Real Estate Investments and Mosaic Development Partners, today announced the execution of an agreement which provides Ensemble/Mosaic with the exclusive development rights for 109 acres at the Navy Yard and launches a $2.5 billion development plan that will create thousands of construction and permanent jobs.

The $400 million first phase includes development of two advanced life sciences buildings followed by significant residential and hospitality initiatives. Ensemble/Mosaic will construct a +/-100,000 square foot speculative laboratory and office development at 1201 Normandy Place with anticipated delivery by the close of 2022. The partners will concurrently market 333 Rouse Boulevard, which can accommodate a 120,000 square foot build-to-suit facility, for opportunities with cGMP (current Good Manufacturing Practice) manufacturers. Upon completion of these buildings the Navy Yard will eclipse one million square feet of life sciences space.

“Execution of the development agreement with Ensemble and Mosaic and commencement of their initial life sciences projects will launch the next exciting chapter of development at the Navy Yard.  Expanding this vibrant life sciences hub will bring high quality jobs to the Navy Yard, support growing companies in the advanced life sciences sector, and contribute to development of this dynamic campus that is already home to 15,000 employees,” said Kate McNamara, Senior Vice President, PIDC. “Equally exciting, our agreement includes one of the most intentional and inclusive economic opportunity initiatives in the history of this city.”

Ensemble Owned and Ensemble Mosaic Development Rights at the Navy Yard

Mosaic Development Partners is a Philadelphia based firm which specializes in commercial and mixed-use development. Since 2012, Mosaic has secured and invested more than $120 million in Philadelphia neighborhoods, bringing quality retail, commercial, recreational, and residential space to communities of color, along with hundreds of construction and full-time jobs.

Smallwood-Lewis said, “For the last eight years, Mosaic has built profitably with community and cultural sensitivity in mind, and this project is in many ways a culmination of our experience to date. The next phase of development Navy Yard represents a unique opportunity to build community and add density, while making the most of the waterfront access and incredible open spaces that have already grown in use and importance during this past year. It is an exciting time, and we are pleased to partner with PIDC and Ensemble in this effort.”

The agreement, which was initially announced last July, will guide the growth and expansion of the former military base and will further establish the Navy Yard as a vibrant and inclusive mixed-use community. Ensemble/Mosaic ultimately envisions approximately 3,000 residential units and nearly three million square feet of life science manufacturing, R&D, office, hotels, makerspace and retail space when complete.

Phase One of Ensemble/Mosaic development at the Navy Yard

Expanding Life Science Capacity is a Top Priority

The building at 1201 Normandy Place is designed by DIGSAU, an award-winning contemporary architecture firm, in collaboration with CRB, a global architecture and engineering firm, which together aims to set a new standard for innovation. Philadelphia-based DIGSAU has designed five buildings in the Navy Yard. CRB is a preeminent designer for life science manufacturing and laboratory environments.

The four-story facility targeting LEED Gold certification is conceived with flexibility at the forefront. Its 30,000 square foot floor plates with 16’ floor-to-floor heights will provide lab and clinical manufacturing-ready environments for ATMP (advanced therapy medicinal products) and life science companies. Spaces between 5,000 to 100,000 square feet will be available, maximizing both efficiency and optionality for the company’s operations.

“Located minutes from University City, the home of cell and gene therapy research, the Navy Yard is a critical component in the growth of life science companies in the region. It will allow companies to incubate, commercialize and manufacture within 15 minutes of each other and an international airport,” said Seltzer. “Our new buildings will create much-needed inventory for the incredible demand for space in this sector.”

The preliminary concept for 333 Rouse Boulevard is a 120,000 square foot facility providing office, laboratory space, cGMP manufacturing, warehousing and conditioned indoor mechanical space for plant and critical utilities. The manufacturing area will support interior ceiling heights up to 16’ and provide floor heights designed to facilitate cGMP manufacturing with walkable cleanroom ceiling systems.

The project provides for a balance of short-term efficiency and long-term flexibility, making it an ideal home to life sciences companies seeking immediate functionality and the ability to grow in place. This project is being designed by DIGSAU and IPS-Integrated Projects Services, LLC, a locally founded company that ranks as one of the top biologics, cell and gene therapy design firms in the world solely dedicated to designing, constructing and qualifying cGMP facilities.

Diversity, Equity, and Inclusion Strategy Drives Development

A key aspect of the vision of this dynamic and vibrant campus is that it provides opportunities for all Philadelphians. To that end, the partners are committed to deploying a robust and novel approach to diversity, equity, and inclusion in all elements of the 109 acres in the agreement.

“From the teams we assemble to design and build the buildings, to the projects and people who will occupy them, the Navy Yard will be a more inclusive place for all,” said Reaves. “Our collective goal is to create a national model that combines institutional development and inclusive strategies in new and exciting ways.”

This holistic inclusion strategy provides tremendous opportunities for minority- and women-owned business enterprise (M/WBE) participation. This will include diverse equity ownership with an innovative crowd-funding component, substantial M/WBE participation in construction and operations, inclusion of local and M/WBE small businesses in retail and makerspace opportunities, a paid internship program with Cheyney University, and the allocation of a share of net income to a charitable foundation that will create new opportunities for young people in Philadelphia. Additional details will be released at another time.

“These and other initiatives will attract female and minority students in high school and college from across the region and the country who are interested in pursuing a career in commercial real estate, construction, architecture and design. It’s not just about planning and building for now, it’s about doing so for the future, too,” Reaves added.

Background

In September 2019, PIDC put out a call for prospective partners through a Request for Qualifications (RFQ). PIDC received more than 35 responses to the RFQ in December 2019. Based on the RFQ criteria, five highly experienced teams were shortlisted and invited to submit full proposals in response to a comprehensive Request for Proposals (RFP). After detailed review and evaluation of the proposals and virtual team interviews with an Advisory Panel, PIDC selected the Ensemble/Mosaic co-development team in July 2020.

In January 2021, PIDC and Ensemble/Mosaic released a Request for Proposals (RFP) opportunity for large-scale comprehensive master planning at the Navy Yard. The team sought proposals from qualified, experienced, diverse, and inclusive planning, design, and engineering firms to develop and deliver a comprehensive master plan. The 2021 Navy Yard Master Plan Update will establish a dynamic, cohesive, and achievable placemaking vision and development framework as the Navy Yard embarks on its next phase of expansion and growth. An announcement about the master plan firm will be made in the coming weeks.

PIDC retained JLL in early 2019 to advise in this selection of a development partner. JLL supported PIDC throughout the RFQ and RFP processes, and assisted PIDC with development agreement negotiations.

Click for additional information about PIDC, the Navy Yard, Ensemble, or Mosaic.

300 Rouse Boulevard, view from Central Green. Credit: DIGSAU

Iovance Biotherapeutics Announces New Facility at the Navy Yard to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a lease agreement to build an approximately 136,000 square foot commercial-scale production facility at the Philadelphia Navy Yard for commercial and clinical production of autologous TIL products, including its candidate lifileucel. Read more

2016-10-06-10-48-15

Ribbon Cut on Third Laboratory Facility for WuXi AppTec at the Navy Yard

Liberty Property Trust and PIDC  joined WuXi AppTec, Inc., a global leader in pharmaceuticals, biopharmaceuticals, and medical devices, for a ribbon cutting ceremony to open their third facility at the Navy Yard.  This new 150,000 square foot facility which, when fully operational, has the potential to accommodate an additional 200 high tech manufacturing and support jobs. Read more